CORE beneficiary partner Syncom and Mercachem, two of the leading European drug discovery Contract Research Organizations (CRO), today announced that the two companies are joining forces effective immediately. The resulting Mercachem-Syncom Group, with more than 300 employees and operations in Nijmegen and Groningen, the Netherlands and Prague, Czech Republic, becomes the premier European mid-sized CRO offering innovative best-in-class chemistry solutions.
Since their inception in 1997 and 1988 respectively, Mercachem and Syncom have established themselves as two of Europe’s leading drug discovery CROs with a focus on high-quality chemistry services to large and mid-size pharmaceutical, life sciences and innovative chemistry customers worldwide. Today’s merger enables the Mercachem-Syncom Group to broaden its offering of integrated drug discovery services and invest into state-of-the-art knowledge base and facilities to address clients’ growing demand for outsourcing solutions. The merger of Mercachem and Syncom and the Group’s growth strategy with a further expansion both organically as well as through partnerships and further acquisitions is supported by Gilde Healthcare, a leading investor in healthcare together with Dutch pension fund service provider PGGM, as co-investor.
See full press release at https://syncom.nl/mercachem-and-syncom-join-forces/
University of Strathclyde Press Release, Crystal Growth Competition
Pupils take crystal-growing challenge at Strathclyde.... more
ESR, Francesca Cascella awarded Best Poster Award at 25th International Workshop on Industrial Crystallization (BIWIC), Rouen
Francesca Cascella based at Otto-von-Guericke University, Magdeburg won the First Place, Best Poster Award at the 25th International Workshop on Industrial Crystallization (BIWIC), 6-7 September 2018, University of Rouen, France.... more